<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763307</url>
  </required_header>
  <id_info>
    <org_study_id>EGFRI-MER-1a-HMO-CTIL</org_study_id>
    <nct_id>NCT01763307</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI</brief_title>
  <acronym>EGFRI</acronym>
  <official_title>A Phase II Randomized, Double Blind, Placebo Study to Evaluate the Efficacy of Vitamin K1 Cream Treatment Compared to Placebo for the Prevention of Papulo-pustular Rash in Metastatic Colorectal Patients Receiving First Line EGFRI Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin K1 cream may prevent papulopustular rash induced by EGFRI given to metastatic
      colorectal cancer patients.

      This study will prospectively accrue metastatic colorectal patients receiving EGFRI and treat
      with reconval cream half face versus placebo cream half face to study whether Vitamin k1
      cream can prevent the typical skin eruption caused by EGFRI.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Potential reduction in skin toxicity by Vitamin K1 cream in metastatic colorectal patients treated with EGFRI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reduction in numbers of papulo-pustular eruptions in the treatment fields compared to the placebo treated side. Changes in follicular eruptions, dryness/redness of skin estimated by the grading scale developed by the Multinational Association of Supportive Care in Cancer (MASCC) skin toxicity study group 4.0. Patients own experience of efficacy estimated by questionnaire.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Rash Due to Epidermal Growth Factor Receptor Inhibitors</condition>
  <arm_group>
    <arm_group_label>RECONVAL CREAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>half face treated with RECONVAL CREAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>half face treated with PLACEBO cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RECONVAL CREAM</intervention_name>
    <arm_group_label>RECONVAL CREAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  metastatic colon cancer patients

          -  male or female

          -  age&gt; 18

          -  treated EGFRI

        Exclusion Criteria:

          -  prior treatment with EGFRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Merims, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medcial Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hadas` Lemberg, PHD LLB</last_name>
    <phone>+972 2 6776095</phone>
    <email>lhadas@hadassah.org.il</email>
  </overall_contact>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2012</study_first_submitted>
  <study_first_submitted_qc>January 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2013</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFRI</keyword>
  <keyword>COLON CANCER</keyword>
  <keyword>SKIN TOXICITY</keyword>
  <keyword>RECONVAL K1 cream</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

